(Q48655811)

13 February 2018

title

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients (English)

1 reference

13 February 2018

Erratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

1 reference

1 reference

corrigendum / erratum

1 reference

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/MP.2012.108

author

Pedro Dorado

3

1 reference

13 February 2018

Marisol López-López

object named as

M López-López

8

0 references

author name string

E M Peñas-Lledó

1

1 reference

13 February 2018

H D Trejo

2

1 reference

13 February 2018

A Ortega

4

1 reference

13 February 2018

H Jung

5

1 reference

13 February 2018

E Alonso

6

1 reference

13 February 2018

M E G Naranjo

7

1 reference

13 February 2018

A Llerena

9

1 reference

13 February 2018

A Llerena

10

1 reference

13 February 2018

language of work or name

English

0 references

publication date

26 June 2012

1 reference

13 February 2018

published in

Molecular Psychiatry

1 reference

13 February 2018

volume

18

1 reference

13 February 2018

issue

1

1 reference

13 February 2018

page(s)

8-9

1 reference

13 February 2018

Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

Adherence to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

CYP2D6 and the severity of suicide attempts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2012.91

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MP.2012.91

1 reference

13 February 2018

release_na5tae6kbfdkzmgu6t5yhnpmbm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/na5tae6kbfdkzmgu6t5yhnpmbm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

13 February 2018